BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12070031)

  • 1. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
    Spanswick VJ; Craddock C; Sekhar M; Mahendra P; Shankaranarayana P; Hughes RG; Hochhauser D; Hartley JA
    Blood; 2002 Jul; 100(1):224-9. PubMed ID: 12070031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
    Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
    PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
    Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
    Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
    Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
    BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
    Efferth T; Fabry U; Osieka R
    Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.
    Souliotis VL; Dimopoulos MA; Sfikakis PP
    Clin Cancer Res; 2003 Oct; 9(12):4465-74. PubMed ID: 14555520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.
    Stefanou DT; Episkopou H; Kyrtopoulos SA; Bamias A; Gkotzamanidou M; Bamia C; Liakou C; Bekyrou M; Sfikakis PP; Dimopoulos MA; Souliotis VL
    Br J Clin Pharmacol; 2012 Nov; 74(5):842-53. PubMed ID: 22432918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.
    Gkotzamanidou M; Terpos E; Bamia C; Munshi NC; Dimopoulos MA; Souliotis VL
    Blood; 2016 Sep; 128(9):1214-25. PubMed ID: 27443291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
    Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP
    J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
    Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
    Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
    Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
    Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of DNA repair in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic response.
    Buschfort-Papewalis C; Moritz T; Liedert B; Thomale J
    Blood; 2002 Aug; 100(3):845-53. PubMed ID: 12130494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
    Pu Q; Bianchi P; Bezwoda WR
    Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
    Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
    Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
    Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
    Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
    Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
    DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
    Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
    Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
    Xiong T; Wei H; Chen X; Xiao H
    Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.